{"success":true,"data":{"pressRelease":{"id":"170280","rtpr_id":"nGNX5TRLJ1-20261015","ticker":"ALMDT","exchange":"Euronext Paris","all_tickers":["ALMDT"],"title":"Eyonis to Present Clinical Evidence for AI-Powered Lung Cancer Screening at CHEST 2026","author":"Globe Newswire","published_at":"2026-10-15T12:05:00.096Z","article_body":"SAN FRANCISCO, CA and SOPHIA ANTIPOLIS, France, Oct. 15, 2026 (GLOBE NEWSWIRE)\n-- October 15, 2026 — Eyonis Inc.\n(https://www.globenewswire.com/Tracker?data=tK8irGvx1NskapnedGTYPkzf9gL8r_bjSTrUP3PwHi40lKK0oBn2GBpgBJGAfcDf8pOHqdJ2PWW9skFvjI0bpA==),\na Median Technologies company focused on AI for cancer detection and\ndiagnosis, will present clinical evidence supporting eyonis® LCS, its\nFDA-cleared AI-powered lung cancer screening software, at CHEST 2026\n(https://www.globenewswire.com/Tracker?data=ksT6ibBHZGqeYaj2MpKEDC_FEbCI4Vf0oq87QshGNDqKf8pkNT2OxoEEigPMg2-ZkfxpUn5qf_yRAsxxyrlJpwjKbn_7vZVRuw7DvN0cjZOp7ZNeK1KWcLAJ7vMmXVHpPWrwB02JxgGqPLXpQfcohw==),\nthe annual meeting of the American College of Chest Physicians, taking place\nOctober 18–21 in Phoenix.\n\nThe presentation will bring the clinical evidence used to establish eyonis LCS\nperformance to the pulmonology community, including results from a\n2,163-patient study supporting the software’s FDA-cleared use in lung cancer\nscreening.\n\nLung cancer screening can identify pulmonary nodules at an earlier stage, but\nfinding a nodule is only the first step. Clinicians must then determine which\nfindings are most concerning and which patients may require additional\nevaluation.\n\neyonis LCS is designed to support that process by combining computer-aided\ndetection (CADe) of pulmonary nodules with computer-aided diagnosis (CADx)\nthat provides radiologists with a nodule-specific malignancy score. The\nsoftware is intended to support clinicians as they evaluate pulmonary nodules\ndetected during low-dose CT lung cancer screening.\n\n“Finding a pulmonary nodule is only the beginning of the lung cancer\nscreening process,” said Oran Muduroglu, President of Eyonis Inc. “The\nnext question is whether that nodule is concerning enough to warrant\nadditional evaluation. CHEST gives us an opportunity to discuss with\npulmonologists how AI can support both detection and malignancy assessment\nwhile keeping the clinician at the center of the decision.”\n\nClinical evidence to be presented at CHEST\n\nBenoit Huet, PhD, Senior Vice President, AI Engineering and Research at Median\nTechnologies, will present the abstract, “Artificial Intelligence for Lung\nCancer Screening: Patient-Level Performance of a Computer-Aided\nDetection/Diagnosis Software as a Medical Device.” The research includes\nco-authors from Assistance Publique-Hôpitaux de Paris and Brigham and\nWomen’s Hospital.\n\nIn the 2,163-patient study, eyonis LCS demonstrated strong patient-level\nperformance, with 93.3% sensitivity, 92.4% specificity, 99.9% negative\npredictive value and an AUC of 0.977.\n\nThe results demonstrate the software’s ability to aid clinicians in\nidentifying patients with lung cancer while minimizing false positive results\nthat may lead to unnecessary and potentially dangerous invasive procedures. In\nreader testing, use of eyonis LCS reduced false-positive findings by 68%\ncompared with radiologists alone—roughly two-thirds fewer suspicious\nfindings for clinicians and nodule clinics to sort through.\n\nThe 0.977 AUC and nodule-specific malignancy score also provide additional\ninformation that can help radiologists and pulmonologists decide with greater\nconfidence whether a higher-risk finding warrants earlier diagnostic work-up,\nsuch as PET/CT or biopsy. \n\nPresentation: Artificial Intelligence for Lung Cancer Screening: Patient-Level\nPerformance of a Computer-Aided Detection/Diagnosis Software as a Medical\nDevice\nPresenter: Benoit Huet, PhD, Senior Vice President, AI Engineering and\nResearch, Median Technologies\nSession: AI in Lung Cancer Screening and Diagnosis\nDate and time: October 19, 2026, 10:20–10:50 a.m.\nLocation: Exhibit Hall Rapid Fire Area 3D \n\nEyonis in Booth #1221\n\nThroughout the conference, Eyonis will demonstrate eyonis LCS at Booth #1221\nand meet with pulmonologists, radiologists, lung cancer screening program\nleaders and other clinicians interested in the role of AI in lung cancer\nscreening.\n\nThe software received FDA 510(k) clearance in February 2026 and is\ncommercially available in the United States.\n\nCHEST provides an opportunity for Eyonis to engage with pulmonologists, who\nplay a central role in lung cancer screening and in evaluating and managing\npatients with suspicious pulmonary nodules.\n\nAbout Eyonis\n\nEyonis, a Median Technologies company, commercializes AI-powered Software as a\nMedical Device for the early detection and diagnosis of cancer. Its flagship\nproduct, eyonis® LCS, analyzes low-dose CT scans to detect suspicious lung\nnodules and assess their likelihood of malignancy. eyonis LCS received FDA\nclearance in the United States in February 2026 and CE marking in Europe in\nJuly 2026. To learn more, visit eyonis.ai\n(https://www.globenewswire.com/Tracker?data=AIsUYEe2jC93O7Ipragf49dzeFZKkpwncYety56sHO_MKacHxXIYTdL2y0mSFctDaBor8IjLSy3jgF3YLjaoJQ==).\n\nAbout Median Technologies\n\nMedian Technologies provides AI-powered medical imaging solutions for cancer\ndiagnosis, treatment and drug development. The company operates through two\nbusinesses: Eyonis, which develops AI-powered Software as a Medical Device for\ncancer detection and diagnosis, and iCRO, which provides imaging services for\noncology clinical trials. Headquartered in France with operations in the\nUnited States and China, Median Technologies is listed on Euronext Growth\nParis under the ticker ALMDT. To learn more, visit\nhttps://mediantechnologies.com/  \n\n\n\nAttachment\n*     Benoit Huet\n(https://ml.globenewswire.com/Resource/Download/18ca012d-e987-40b5-9a2d-6cab3b14f1b1)\nTodd Stein\neyonis\n5104170612\ntodd@toddsteincommunications.com\n\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5TRLJ1-20261015","title":"Eyonis to Present Clinical Evidence for AI-Powered Lung Cancer Screening at CHEST 2026","author":"Globe Newswire","ticker":"ALMDT","created":"2026-10-15T12:05:00.096Z","tickers":["ALMDT"],"exchange":"Euronext Paris","article_body":"SAN FRANCISCO, CA and SOPHIA ANTIPOLIS, France, Oct. 15, 2026 (GLOBE NEWSWIRE)\n-- October 15, 2026 — Eyonis Inc.\n(https://www.globenewswire.com/Tracker?data=tK8irGvx1NskapnedGTYPkzf9gL8r_bjSTrUP3PwHi40lKK0oBn2GBpgBJGAfcDf8pOHqdJ2PWW9skFvjI0bpA==),\na Median Technologies company focused on AI for cancer detection and\ndiagnosis, will present clinical evidence supporting eyonis® LCS, its\nFDA-cleared AI-powered lung cancer screening software, at CHEST 2026\n(https://www.globenewswire.com/Tracker?data=ksT6ibBHZGqeYaj2MpKEDC_FEbCI4Vf0oq87QshGNDqKf8pkNT2OxoEEigPMg2-ZkfxpUn5qf_yRAsxxyrlJpwjKbn_7vZVRuw7DvN0cjZOp7ZNeK1KWcLAJ7vMmXVHpPWrwB02JxgGqPLXpQfcohw==),\nthe annual meeting of the American College of Chest Physicians, taking place\nOctober 18–21 in Phoenix.\n\nThe presentation will bring the clinical evidence used to establish eyonis LCS\nperformance to the pulmonology community, including results from a\n2,163-patient study supporting the software’s FDA-cleared use in lung cancer\nscreening.\n\nLung cancer screening can identify pulmonary nodules at an earlier stage, but\nfinding a nodule is only the first step. Clinicians must then determine which\nfindings are most concerning and which patients may require additional\nevaluation.\n\neyonis LCS is designed to support that process by combining computer-aided\ndetection (CADe) of pulmonary nodules with computer-aided diagnosis (CADx)\nthat provides radiologists with a nodule-specific malignancy score. The\nsoftware is intended to support clinicians as they evaluate pulmonary nodules\ndetected during low-dose CT lung cancer screening.\n\n“Finding a pulmonary nodule is only the beginning of the lung cancer\nscreening process,” said Oran Muduroglu, President of Eyonis Inc. “The\nnext question is whether that nodule is concerning enough to warrant\nadditional evaluation. CHEST gives us an opportunity to discuss with\npulmonologists how AI can support both detection and malignancy assessment\nwhile keeping the clinician at the center of the decision.”\n\nClinical evidence to be presented at CHEST\n\nBenoit Huet, PhD, Senior Vice President, AI Engineering and Research at Median\nTechnologies, will present the abstract, “Artificial Intelligence for Lung\nCancer Screening: Patient-Level Performance of a Computer-Aided\nDetection/Diagnosis Software as a Medical Device.” The research includes\nco-authors from Assistance Publique-Hôpitaux de Paris and Brigham and\nWomen’s Hospital.\n\nIn the 2,163-patient study, eyonis LCS demonstrated strong patient-level\nperformance, with 93.3% sensitivity, 92.4% specificity, 99.9% negative\npredictive value and an AUC of 0.977.\n\nThe results demonstrate the software’s ability to aid clinicians in\nidentifying patients with lung cancer while minimizing false positive results\nthat may lead to unnecessary and potentially dangerous invasive procedures. In\nreader testing, use of eyonis LCS reduced false-positive findings by 68%\ncompared with radiologists alone—roughly two-thirds fewer suspicious\nfindings for clinicians and nodule clinics to sort through.\n\nThe 0.977 AUC and nodule-specific malignancy score also provide additional\ninformation that can help radiologists and pulmonologists decide with greater\nconfidence whether a higher-risk finding warrants earlier diagnostic work-up,\nsuch as PET/CT or biopsy. \n\nPresentation: Artificial Intelligence for Lung Cancer Screening: Patient-Level\nPerformance of a Computer-Aided Detection/Diagnosis Software as a Medical\nDevice\nPresenter: Benoit Huet, PhD, Senior Vice President, AI Engineering and\nResearch, Median Technologies\nSession: AI in Lung Cancer Screening and Diagnosis\nDate and time: October 19, 2026, 10:20–10:50 a.m.\nLocation: Exhibit Hall Rapid Fire Area 3D \n\nEyonis in Booth #1221\n\nThroughout the conference, Eyonis will demonstrate eyonis LCS at Booth #1221\nand meet with pulmonologists, radiologists, lung cancer screening program\nleaders and other clinicians interested in the role of AI in lung cancer\nscreening.\n\nThe software received FDA 510(k) clearance in February 2026 and is\ncommercially available in the United States.\n\nCHEST provides an opportunity for Eyonis to engage with pulmonologists, who\nplay a central role in lung cancer screening and in evaluating and managing\npatients with suspicious pulmonary nodules.\n\nAbout Eyonis\n\nEyonis, a Median Technologies company, commercializes AI-powered Software as a\nMedical Device for the early detection and diagnosis of cancer. Its flagship\nproduct, eyonis® LCS, analyzes low-dose CT scans to detect suspicious lung\nnodules and assess their likelihood of malignancy. eyonis LCS received FDA\nclearance in the United States in February 2026 and CE marking in Europe in\nJuly 2026. To learn more, visit eyonis.ai\n(https://www.globenewswire.com/Tracker?data=AIsUYEe2jC93O7Ipragf49dzeFZKkpwncYety56sHO_MKacHxXIYTdL2y0mSFctDaBor8IjLSy3jgF3YLjaoJQ==).\n\nAbout Median Technologies\n\nMedian Technologies provides AI-powered medical imaging solutions for cancer\ndiagnosis, treatment and drug development. The company operates through two\nbusinesses: Eyonis, which develops AI-powered Software as a Medical Device for\ncancer detection and diagnosis, and iCRO, which provides imaging services for\noncology clinical trials. Headquartered in France with operations in the\nUnited States and China, Median Technologies is listed on Euronext Growth\nParis under the ticker ALMDT. To learn more, visit\nhttps://mediantechnologies.com/  \n\n\n\nAttachment\n*     Benoit Huet\n(https://ml.globenewswire.com/Resource/Download/18ca012d-e987-40b5-9a2d-6cab3b14f1b1)\nTodd Stein\neyonis\n5104170612\ntodd@toddsteincommunications.com\n\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-15T12:05:00.139799616Z","server_sent_at_ms":1792065900139},"received_at":"2026-10-15T12:05:00.190Z","source_url":null},"analysis":{"id":"158478","press_release_id":"170280","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Eyonis Inc., a Median Technologies (Euronext Growth Paris: ALMDT) subsidiary, will present clinical evidence for its FDA-cleared eyonis LCS lung cancer screening AI at CHEST 2026 in Phoenix on October 19.\n\nThe data comes from a 2,163-patient study showing 93.3% sensitivity, 92.4% specificity, a 99.9% negative predictive value and an AUC of 0.977, with reader testing showing a 68% reduction in false positives versus radiologists alone.\n\neyonis LCS received FDA 510(k) clearance in February 2026 and CE marking in July 2026; the presentation is a commercial-marketing push with pulmonologists, the key adoption audience for the software.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Conference showcase of previously cleared AI lung-screening software -- modest commercial momentum signal for ALMDT."},"keyFigures":{"customDimensions":{"auc":0.977,"ce_mark":"July 2026","sensitivity":"93.3%","specificity":"92.4%","study_patients":2163,"fda_510k_clearance":"February 2026","false_positive_reduction":"68%","negative_predictive_value":"99.9%"}},"quotedText":"Finding a pulmonary nodule is only the beginning of the lung cancer screening process","namedEntities":{"people":[{"name":"Oran Muduroglu","role":"President of Eyonis Inc."},{"name":"Benoit Huet, PhD","role":"Senior Vice President, AI Engineering and Research, Median Technologies"},{"name":"Todd Stein","role":"media contact"}],"products":["eyonis LCS"],"companies":[{"name":"Eyonis Inc.","ticker":"ALMDT","relationship":"subsidiary presenting the data"},{"name":"Median Technologies","ticker":"ALMDT","relationship":"parent company of the filer"},{"name":"American College of Chest Physicians (CHEST 2026)","relationship":"conference host"},{"name":"Assistance Publique-Hôpitaux de Paris","relationship":"research co-author institution"},{"name":"Brigham and Women's Hospital","relationship":"research co-author institution"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"A conference presentation of already-disclosed clinical data for an FDA-cleared product; no new regulatory, financial, or trial information."},"tickerRelevance":{"others":[],"primary":"ALMDT"},"globalImportance":18,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"novelData":false,"tickerTier":"micro-cap foreign-listed","eventGravity":"conference-data-presentation","commercialMomentum":true}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Eyonis Inc., a Median Technologies (Euronext Growth Paris: ALMDT) subsidiary, will present clinical evidence for its FDA-cleared eyonis LCS lung cancer screening AI at CHEST 2026 in Phoenix on October 19.\n\nThe data comes from a 2,163-patient study showing 93.3% sensitivity, 92.4% specificity, a 99.9% negative predictive value and an AUC of 0.977, with reader testing showing a 68% reduction in false positives versus radiologists alone.\n\neyonis LCS received FDA 510(k) clearance in February 2026 and CE marking in July 2026; the presentation is a commercial-marketing push with pulmonologists, the key adoption audience for the software.","key_figures":{"customDimensions":{"auc":0.977,"ce_mark":"July 2026","sensitivity":"93.3%","specificity":"92.4%","study_patients":2163,"fda_510k_clearance":"February 2026","false_positive_reduction":"68%","negative_predictive_value":"99.9%"}},"named_entities":{"people":[{"name":"Oran Muduroglu","role":"President of Eyonis Inc."},{"name":"Benoit Huet, PhD","role":"Senior Vice President, AI Engineering and Research, Median Technologies"},{"name":"Todd Stein","role":"media contact"}],"products":["eyonis LCS"],"companies":[{"name":"Eyonis Inc.","ticker":"ALMDT","relationship":"subsidiary presenting the data"},{"name":"Median Technologies","ticker":"ALMDT","relationship":"parent company of the filer"},{"name":"American College of Chest Physicians (CHEST 2026)","relationship":"conference host"},{"name":"Assistance Publique-Hôpitaux de Paris","relationship":"research co-author institution"},{"name":"Brigham and Women's Hospital","relationship":"research co-author institution"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-15T12:05:06.075Z","global_importance":18,"audience_relevance":12,"importance_components":{"novelData":false,"tickerTier":"micro-cap foreign-listed","eventGravity":"conference-data-presentation","commercialMomentum":true}},"durationMs":5876,"modelName":"glm-5.3-flashx"}}